Alpha Cognition Inc
ACOG
Kedudukan dalam Saham
#20190
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Harga Saham
$8.47
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$131.47M
Perubahan (1 hari)
3.36%
Perubahan (1 tahun)
68.29%
Negara
US
Perdagangan Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Nisbah P/S bagi Alpha Cognition Inc (ACOG)
Nisbah P/S pada October 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Alpha Cognition Inc, nisbah P/S semasa (TTM) ialah 0.00. Pada akhir 2022, nisbah P/S syarikat ialah 0.00.
Sejarah nisbah P/S untuk Alpha Cognition Inc dari 2018 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
